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Serum ferritin assay and bone-marrow iron stores in mainte-
nance hemodialysis patients. Fifty-five patients on maintenance
hemodialysis underwent bone marrow aspirations for evaluation
of iron stores that were to be compared to concomitant measure-
ments of hematocrit, red blood cell volume, serum iron concen-
tration, total iron binding capacity, transferrin saturation, and
serum ferritin concentration. In 42 patients (76.4%), the bone-
marrow iron stores were found to be absent or deficient. Mean
hematocrit for the total group was 26.4%, and red blood cell vol-
ume measurement showed a mean value of 41.1% of predicted
normal, Results also indicated that serum ferritin was the best
predictor of iron storage levels, with diagnostic thresholds of 80
to 350 nglml derived from statistical analysis of the data. Other
hematologic parameters studied had significantly less correlation
with bone-marrow iron stores.
Dosage de Ia ferritine sérique et reserves médullaires de fer au
cours de I'hémodialyse chronique. Cinquante cinq malades en
hémodialyse chronique ont subi des ponctions de moelle osseuse
pour l'évaluation des reserves de fer, evaluation qui a été corn-
parée aux mesures de l'hématocrite, du volume érythrocytaire,
du fer sérique, de Ia capacité totale de fixation du fer, de Ia satu-
ration de Ia transfernne et de Ia ferritine sérique. Chez 42 malad-
es (76,4%) les reserves médullaires de fer étaient nulles ou in-
suffisantes. L'hCmatocrite moyen pour Ia totalité du groupe était
de 26,4% et le volume globulaire moyen était a 41,1%, en
moyenne, de Ia valeur théorique. Les résultats indiquent que Ia
ferritine serique est le meilleur élément de prediction des ré-
serves de fer avec un seuil diagnostic de 80 a 350 ng/ml d'après
lanalyse statistique des résultats. Les autres paramètres héma-
tologiques étudiés avaient significativement moms de correlation
avec les reserves médullaires du fer.
Anemia in the patient on maintenance hemo-
dialysis is virtually universal and may be severe
enough to interfere significantly with patient reha-
bilitation. Its pathogenesis is multifactorial [1—3]
and includes the relative lack of erythropoietin, he-
molysis, toxic suppression of erythropoiesis, and
deficiency states of water-soluble vitamins, folic
acid, and iron. Many of these factors are either
poorly understood or cannot be easily quantitated
in the individual patient, which creates a variety of
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empiric therapies for anemia in the dialysis popu-
lation.
Especially prevalent is the empiricism regarding
iron therapy in the patient on maintenance hemo-
dialysis. The administration of oral iron is sub-
stantially routine, and the i.v. treatment with iron
dextran is not uncommon. It is well documented
that, in the patient on hemodialysis, a significant
iron deficit that exceeds dietary intake occurs from
blood loss [2, 4—6]. This occurs primarily as a result
of dialyzer blood loss, blood sampling, and occult
gastrointestinal blood loss. Current evidence sug-
gests that the intrinsic mechanisms for intestinal
iron absorption are normal in patients with chronic
renal failure and in patients on maintenance dialysis
[7-10]. The quantitation of iron utilization is an un-
certain variable due to, at least in part, its depen-
dence on the adequacy of dialysis [11], the measure-
ment of which is clearly enigmatic.
Because of concern regarding the clinical impact
of both iron-deficiency and iron-overload states, we
have undertaken to define bone-marrow iron stores
in a group of patients on long-term maintenance he-
modialysis and to correlate it with other hematolog-
ic parameters. Specific interest had been generated
for the accuracy of the serum ferritin assay in pre-
dicting iron stores as previously published [12—14].
Methods
Fifty-five patients from the Home Dialysis Pro-
gram at the University of Texas Medical Branch
Received for publication May 4, 1979
and in revised form August 3, 1979
0085-2538/80/0017-0237 $01.00
© 1980 by the International Society of Nephrology
238 Bell et a!
were used for the study. The patients' ages varied
between 21 and 63 years (mean age, 41.2 years).
Average time on dialysis was 4.0 years for the group
(range, 0.6 to 8.5 years). All patients were on main-
tenance hemodialysis with either a Gambro-Lundia
17-p./m2 or a Cordis Dow 1.3-rn2 dialyzer for 18 to 21
hours/week. All patients had a dietary protein in-
take of approximately 1.Og/kg of body weight daily,
and all were taking phosphate-binders, folic acid,
and multivitamins. Virtually all patients received
iron orally, usually administered concomitantly
with meals and phosphate-binders, at an average
daily dosage of 189.2 mg of elemental iron (900 mg
ferrous sulfate/gluconate). None of the patients re-
ceived parenteral iron therapy. Five patients, how-
ever, received blood transfusions or experienced
active inflammation within a 4-week period prior to
their evaluation; they were excluded from the final
results. No patients with liver disease were includ-
ed in the study group. Excellent patient compliance
was suggested by the favorable mortality rate of
1.8%/year and a hospital backup dialysis rate of less
than 3%/year.
Hematocrit, serum iron [15], total iron binding
capacity [16], and transferrin saturation were mea-
sured by standard techniques. The red blood cell
mass was measured by the chromium-SI radio-
isotopic method [17]. Serum ferritin concentrations
were measured by the radioimmunoassay method
of Addison, Beamish, and Hales [18] and the modi-
fication of Miles et al [19]. Bone marrow samples,
aspirated from two separate anatomic sites in most
patients, was stained for hemosiderin with Prussian
blue. The hemosiderin content of the bone marrow
was semiquantitatively estimated by two indepen-
dent hematologists who had no knowledge of the
patients' hematologic status and graded on a scale
of 0 to 3+ [20]. Zero was defined as no hemosiderin
particles in any of the spicules, representing absent
marrow iron stores. 1 + signified only a few hemo-
siderin particles within the marrow, indicative of
depleted marrow iron stores. 2+ represented con-
siderably more hemosiderin than I + within the
marrow, compatible with normal iron stores. 3+ in-
dicated large quantities of hemosiderin, or exces-
sive iron stores. In grading the marrow for hemo-
siderin, there was close correlation between the two
examiners.
Results
Figure 1 provides a histogram depicting the num-
ber of patients in each bone-marrow iron stores
group. Of the 55 patients, 42 (76.4%) had either ab-
sent or decreased iron stores, whereas 4 (7.3%) had
normal and 9 (16.4%) had increased iron stores.
Table I shows the mean values and ranges for he-
matocrit and the various measures of red blood cell
volume for each bone-marrow iron group and for
the total group (53 patients completed this portion
Table 1. Hematocrit and red blood cell volume measurements correlated with bone marrow iron storesa
Marrow iron N Hct
RBC volume"
ml mi/kg %
0(absent) 27 28.5 8.3
(14.0 to 50.0)
1079.3 377.3
(540 to 2030)
15.8 3.7
(9.6 to 22.8)
40.0 10.8
(25.3 to 64.4)
1+ (decreased) 14 25.7 4.7
(18.0 to 33.0)
1018.6 243.4
(620 to 1500)
15.1 2.5
(10.5 to 18.8)
44.8 7.4
(32.6 to 58.5)
2+ (normal) 4 23.0 3.2
(20.0 to 27.0)
652.5 238.7
(520 to 1010)
12.35 4,8
(9.7 to 19.6)
41.0 17.8
(30.3 to 67.6)
3+ (increased) 8 22.6 5.8
(14.0 to 31.0)
819.4 390.8
(460 to 1475)
12.75 3.5
(9.8 to 18.8)
38.3 15.8
(27.9 to 58.8)
Overall mean 26.4
(14.0 to 50.0)
991.8
(460 to 2030)
14.9
(9.6 to 22.8)
41.1
(25.3 to 67.6)
a Values are the means SD. The ranges are in parentheses.
The percentage is obtained by dividing the predicted value into the actual value and multiplying by 100.
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Fig. 1. Distribution of hemodialysis patients studied by bone-
marrow iron stores assessment.
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Table 2. Serum parameters of iron status categorized in regard to bone marrow in storesa
Marrow iro&' N Male/female
Serum iron
pg/dl
T1BC
g/dI
Transferrin
saturation
%
Serum
ferritin
ng/nI
0 28 15/13 64.4 26.2
(23 to 147)
380.1 35.5
(323 to 453)
17.0 7.2
(7 to 43)
27.7 23.3
(4 to 108)
1+ 14 6/8 84.9 55,5
(36 to 262)
390.5 43.1
(320 to 459)
21.3 11.5
(II to 57)
43.4 28.2
(10 to 127)
2+ 4 0/4 97.3 5.9
(91 to 105)
385.3 64.7
(327 to 477)
25.5 2.6
(22 to 28)
181.8 29.4
(140 to 209)
3+ 9 3/6 129.1 56,6
(63 to 261)
331.0 32.4
(261 to 421)
40.8 14.1
(24 to 62)
855.7 482.2
(110 to 1800)
Overall mean 82.6
(23 to 262)
375.1
(261 to 477)
22.6
(7 to 62)
178.4
(4 to 1800)
a Values are the mean SD, with the range given in parentheses.
b 0 to 3+ is defined in Table 1.
TIBC is total iron binding capacity.
Table 3. Correlation ratios between bone marrow iron stores and
various hematologic parameters
Parameter Correlation ratio
Hematocrit 0.312
Red blood cell volume (ml) 0.426
Red blood cell volume (mI/kg) 0.375
Red blood cell volume (actual/predicted) 0.294
Serum iron 0.543
Total iron binding capacity 0.460
Transferrin saturation 0.647
Serum ferritin 0.884
of the study). For the total group, the mean hemato-
crit was 26.4% (range, 14.0% to 50.0%). Red blood
cell volume is represented as the actual milliliters
measured, actual milliliters measured per kilogram
of body weight, and actual milliliters per kilogram
divided by predicted milliliters per kilogram, ex-
pressed as a percentage of predicted normal. The
total group's average red blood cell volumes were
991.8 ml (range, 460 to 2030 ml) and 14.9 mI/kg
(range, 9.6 to 22.8 mI/kg). This was 41.1% of the
predicted value for normal (range, 25.3 to 67.6%).
Table 2 gives mean values and ranges for serum
iron concentration, total iron binding capacity,
transferrin saturation, and serum ferritin concentra-
tion for each bone-marrow iron group and the total
group. In 55 patients, the average serum iron was
82.6 tg'dl (range, 23 to 262 gIdl), total iron binding
capacity averaged 375.1 pg/dl (range, 261 to 477 Lg/
dl), transferrin saturation was 22.6% (range, 7 to
62%), and average serum ferritin was 178.4 ng/ml
(range, 4 to 1800 ng/ml).
For the purposes of statistical analysis, the natu-
ral logarithm of the various hematologic parameters
were taken. The correlation ratio [21] was used to
estimate the degree of association between each he-
matologic parameter and bone marrow iron (the
correlation ratio ranges from 0.00, indicating no as-
sociation, to 1.00, indicating perfect association).
Table 3 presents these results and indicates that the
serum ferritin had the highest degree of positive as-
sociation with marrow iron stores (correlation ratio,
0.884). The degree of association was significant (P
< 0.05) for all variables except hematocrit and red
blood cell volume (actual/predicted).
A discriminant function analysis [22] also in-
dicated that serum ferritin is the best single predic-
tor of bone marrow iron. In addition, the analysis
indicated that the prediction of bone marrow iron
concentration is not significantly improved by con-
sidering serum ferritin concentration in combina-
tion with any of the other hematologic parameters
under study. The discriminant function analysis al-
so provided estimates of decision criteria for pre-
dicting the bone-marrow category, given the serum
ferritin value. The estimated decision criteria are 82
to 354 ng/ml for the normal group (2+), less than 82
ng/ml for the iron-deficient groups (0, 1+), and
greater than 354 ng/ml for the excessive iron stores
group (3+).
Figure 2 compares the predicted bone marrow
categories to the actual categories. It shows that the
derived decision criteria correctly predicted the
bone marrow iron category for 52 of the 55 patients
(94.5%). Two iron-deficient patients and one iron-
excess patient were misclassified as normal; no nor-
mal patients, however, were misclassified. Thus,
the positive predictive value of serum ferritin is
quite high. The negative predictive value is, how-
ever, difficult to judge due to the small number of
patients with normal (2+) values in the present
study.
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Fig. 2. Co,nparison of actual bone-marrow iron category to that
predicted by serum ferritin. Shaded area indicates those that
were predicted accurately.
Discussion
Previously published data [10, 12-14] have sug-
gested that determining the serum ferritin concen-
tration in maintenance hemodialysis patients is
valuable in predicting iron storage levels, and that
other parameters such as serum iron, total iron-
binding capacity, and transferrin saturation are less
reliable for this purpose. Our study corroborates
these earlier findings, with the serum ferritin con-
centration being the best predictor (correlation ra-
tio, 0.884) of marrow iron stores compared with the
other hematologic variables studied. The transferrin
saturation, which is a single parameter than takes
into account both the serum iron and the total iron-
binding capacity, was intermediate in predictive
sensitivity (0.647), but the serum iron and other pa-
rameters were significantly lower. An important
fact is that prior to the availability of the serum fer-
ritin determination, and even now in some centers,
the most common single test used in patients on he-
modialysis to determine their need for additional
iron therapy was the serum iron level, which is
shown to be of limited value in this study.
Normal values for serum ferritin have been diffi-
cult to glean from the current literature, with nor-
mal values ranging from 18 to 330 nglml [10, 12-14,
23, 24]. The reports involving patients on hemo-
dialysis have been limited, however, in the number
of patients studied and in correlations with bone-
marrow iron status. With the discriminant function
analysis performed on the data in our study, it
seems appropriate to select diagnostic thresholds of
80 to 350 ng/ml for determining iron status in pa-
tients on hemodialysis.
It was interesting to note that although the aver-
age hematocrit of the patients included in the study
was reduced from expected normal values by only
25 to 40%, the red blood cell volume was reduced
by almost 60%. This suggests that the hematocrit is
a less-reliable parameter for studying the anemia of
hemodialysis patients due to the effect of concentra-
tion and dilution by extracellular fluid volume vari-
ance at the time of sampling in these patients. Fu-
ture investigations should account for this factor
and should consider using the red blood cell volume
measurement as a more dependable parameter for
the longitudinal followup of the anemia of patients
on dialysis.
Patients with active inflammation or liver disease
were not included in this report due to known ef-
fects upon serum ferritin concentrations, causing
false elevations [25]. Also excluded from examina-
tion were patients who had received blood trans-
fusions within the previous 4 weeks, due to the
knowledge that iron from parenteral sources is not
as readily utilized in the synthesis of hemoglobin as
is iron absorbed from the gastrointestinal tract, thus
falsely increasing the amount of stainable iron in the
bone marrow [26]. Although none of our patients
had received i.v. iron dextran, it would seem impor-
tant to assess its specific effect on improvement of
iron-deficiency anemia in patients on hemodialysis,
due to the suggestion that residual iron dextran
complexes are present in the marrow for up to 6
months after infusion yet are not available for eryth-
ropoiesis [27]. The question that remains to be an-
swered is whether or not i.v. iron dextran produces
"optimal" iron for erythropoiesis without creating
an iron-overload state.
With the knowledge that iron overload can easily
occur with repetitive i.v. therapy [28] and that the
risk of iron overload with oral iron therapy is, in all
probability, very small as iron absorption decreases
markedly in patients with chronic renal failure when
they are iron-replete [10, 29], it seems justified to
suggest that the routine use of i.v. iron dextran
should be attenuated. Oral iron therapy is in-
expensive, essentially free from the risk of anaphy-
laxis, effective, and well-tolerated without side ef-
fects in almost all patients [30].
Conclusion. The results presented indicate the
following. (1) Serum ferritin concentrations corre-
late well with bone-marrow iron stores in patients
on maintenance hemodialysis. (2) Serum ferritin
concentrations less than 80 ng/ml indicate an iron-
depletion state, and a value greater than 350 ng/ml
0,1+ 2+ 3+
(<82) (82-354) 3M)
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suggests excessive marrow iron. (3) Other hemato-
logic parameters show significantly lower correla-
tion with bone-marrow iron stores.
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